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Abstract
Background: The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of 
the high affinity somatostatin receptor subtype 2 analogue, 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in neuroendocrine tumours (NETs). 
Material and methods: 46 patients with disseminated or non-operable NET were enrolled in this study. The 90Y-DOTATATE therapeutic 
activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administered in three to five cycles, repeated every four to 
nine weeks. Before and after the therapy, blood tests for haematology, kidney and liver function, and chromogranin A were performed. 
Results: Out of 46 90Y-DOTATATE treated patients, one died before completing the therapy and 16 died after completing the therapy, 
among them one due to myocardial infarction. After 12 month follow-up, stabilisation of disease was observed in 47%, partial remission in 
31%, and progression in 9% of the 45 patients who completed the therapy. Five patients died before completion of 12 months of follow-up. 
One of the patients died due to myocardial infarction. In one case, the information after 12 months is incomplete. The progression free 
survival was 37.4 months. During 12 months follow-up, transient decrease of PLT, WBC and haemoglobin values was observed. A transient 
increase of creatinine level (within normal ranges) and decrease of GFR values were found. 
Conclusions: NETs 90Y-DOTATATE  therapy results in symptomatic relief and tumour mass reduction. The mild critical organ toxicity does 
not limit the PRRT of NETs. (Pol J Endocrinol 2011; 62 (5): 392–400)
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Streszczenie
Wstęp: Celem pracy była ocena skuteczności oraz toksyczności celowanej terapii receptorowej (PRRT) guzów neuroendokrynnych z wy-
korzystaniem analogu somatostatyny Tyr3-octreotate znakowanego 90Y (90Y-DOTATATE). 
Materiał i metody: Do badania włączono 46 pacjentów z rozsianym lub nieoperacyjnym guzem NET. 90Y-DOTATATE podawano 
w 3–5 kursach w odstępach 4–9-tygodniowych. Każdorazowo wyznaczano aktywność terapeutyczną, uwzględniając taką całkowitą 
powierzchnię ciała, by nie przekroczyć sumarycznej wartości 7,4 GBq/m2. Przed terapią i po niej wykonano oznaczenia parametrów 
morfotycznych, nerkowych oraz wątrobowych, a także stężenia chromograniny A. 
Wyniki: Spośród 46 leczonych pacjentów jeden chory zmarł przed zakończeniem pełnego cyklu terapeutycznego, a 16 po zakończeniu 
terapii, w tym jeden z powodu zawału serca. W 12. miesiącu obserwacji stwierdzono 47% stabilizacji, 31% częściowych odpowiedzi oraz 
9% progresji wśród 45 pacjentów, którzy ukończyli leczenie. Pięciu chorych zmarło przed 12. miesiącem obserwacji. W jednym przypadku 
utracono możliwość uzyskania informacji o chorym po 12 miesiącach. Okres czasu bez progresji choroby wyniósł 37,4 miesiąca. W ciągu 
pierwszego roku od zakończenia terapii zaobserwowano jedynie przejściowe obniżenie wartości morfotycznych krwi oraz przejściowy 
wzrost stężenia kreatyniny i spadek wartości przesączania kłębuszkowego (GFR). 
Wnioski: Celowana terapia receptorowa z użyciem 90Y-DOTATATE może być skuteczną oraz stosunkowo bezpieczną metodą leczenia 
prowadzącą do częściowej odpowiedzi lub stabilizacji choroby u większości pacjentów. (Endokrynol Pol 2011; 62 (5): 392–400)
Słowa kluczowe: terapia znakowanymi analogami somatostatyny, guzy neuroendokrynne, terapia celowana
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Introduction
The management of patients with neuroendocrine 
tumours (NETs) is a challenge to clinicians, inspiring 
the search for new diagnostic and therapeutic proce-
dures. NETs are usually well differentiated neoplasms 
with low response to chemotherapy. The main problems 
with systemic therapy are a lack of selectivity and high 
toxicity for healthy cells. The advantage of targeted 
radionuclide therapy is a selective treatment effect with 
the use of an appropriate ligand carrying the isotope 
directly to the malignant cell population.
The overexpression of somatostatin cell surface 
receptors on different neoplasms, including NETs, 
have become the molecular basis for the application of 
somatostatin analogues in the diagnosis and therapy 
of these tumours.
In recent years, peptide receptor radionuclide therapy 
(PRRT) has been tested, using high affinity receptor sub-
type 2 (sstr2) somatostatin analogues including Tyr3-oc-
treotate labelled with 90Y or 177Lu or combined therapy 
using a mixture of somatostatin analogues labelled with 
90Y and 177Lu. Tyr3-octreotate is the most promising radio-
labelled peptide for treatment purposes [1].
The following 90Y/177Lu labelled somatostatin ana-
logues are the most important: [DOTA, Tyr3] octreotide 
(DOTA TOC), DOTA-lanreotide (DOTA LAN), and 
[DOTA, Tyr3]-octreotate (DOTA TATE) [2, 3].
The Tyr3-octreotate (octreotate) differs from the 
Tyr3-octreotide (octreotide) in that the terminal threo-
nine replaces threoninol. The terminal threonine pro-
vides higher receptor binding, better internalisation, 
and greater tumour irradiation [4, 5].
Yttrium-90 (T1/2 — 64 hours) is a pure beta emitter 
with a maximum range of tissue irradiation of 10 mm. 
The high energy of this radioisotope (935 keV) is suf-
ficient to achieve direct tumour effects. Due to the 
characteristics of 90Y, patients may be discharged from 
hospital soon after treatment [6, 7] 
The type of ligand used in PRRT influences both the 
treatment efficacy as well as therapy side-effects. 90Y la-
belled somatostatin analogues are secreted to glomeruli 
and reabsorbed in proximal canaliculi, causing tracer 
retention in the interstitial area with a concomitant 
increase in kidney irradiation [8, 9]. Therefore, kidneys 
are the critical organs in the therapy using 90Y labelled 
somatostatin analogues.
The indications for radioisotope NET therapy are 
disseminated and/or non-operable somatostatin re-
ceptor overexpressed tumours confirmed by positive 
somatostatin receptor scintigraphy (SRS). The most 
expected advantage of this therapy is partial or com-
plete remission or stabilisation of disease resulting in 
prolongation of life and symptomatic relief.
The aim of this study was to evaluate the efficacy 
and assess the critical organ toxicity of 90Y-DOTATATE 
therapy in patients with disseminated or non-operable 
neuroendocrine tumours.
Material and methods
Forty six patients (27 females, 19 males, aged 31–78; 
mean: 59.7 ± 11.9 years) with histopathologically 
confirmed NET and positive [99mTc-EDDA/HYNIC]
octreotate SRS results were enrolled in the study. 
There were 26 patients with foregut tumours (18 with 
pancreatic neuroendocrine tumours), 11 with midgut 
tumours, two with hindgut tumours, four with medul-
lary thyroid cancer and three with unknown primary 
focus (PFU).
Twenty two patients suffered from hypertension, 
14 patients had a positive history of diabetes, and in ten 
cases both hypertension and diabetes were observed. 
Thirteen (28.3%) of the patients received chemother-
apy at least six months before PRRT. Metastases were 
identified in a majority of patients (89.1%), mainly 
to the liver (71.7%) and to the lymph nodes (32.6%). 
Other distant metastases (bones, lungs, CSN) were 
observed in 41.3% of patients. Thirty one patients un-
derwent surgical treatment before PRRT, four patients 
underwent explorative laparotomy. Eleven patients 
(24%) were not operated due to the inoperable nature 
of their tumours or due to cardiac contraindications 
to the surgery (two patients). Four of the patients 
who were not operated did not present with distant 
metastases. Before admission to our department and 
referral for PRRT, 13 patients received chemotherapy 
due to disseminated progressive disease or as neoad-
juvant therapy (five with streptozotocin/5-FU, one 
with etoposide/cisplatine, one with cisplatine/vepesid, 
one with etoposide, one with FDE, two with Gemzar, 
one with PLFE and one with 5-FU and leucovorine) 
because of lack of other therapeutic modalities at the 
time of diagnosis. Three patients underwent local ra-
diotherapy — two women due to eye and thoracic wall 
metastases, and one man due to bone (spinal column) 
metastases. Ten patients received a long-acting soma-
tostatin analogue (Sandostatin LAR) due to carcinoid 
syndrome. The treatment in all cases was no longer 
than three months.
Inclusion criteria for PRRT therapy were:
 — progressive disease according to RECIST defined as 
at least 20% increase in size of at least one neoplas-
matic lesion (also in patients after other therapeutic 
approaches) or inoperable primary tumour and/or 
lack of symptoms control with biotherapy (somato-
statin analogue treatment);
 — positive [99mTc-EDDA/HYNIC] octreotate SRS;
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 — blood morphology: white blood cells (WBC) 
> 3,000/μl, platelets (Plt) > 100,000 /μl, Hb > 10 g/L;
 — renal parameters: blood urea nitrogen (BUN)
< 10 mmol/L, creatinine < 160 μmol/L, and glomeru-
lar filtration rate (GFR) > 30 mL/min;
 — written informed consent to the therapy.
Exclusion criteria were:
 — Karnofsky’s performance index < 50;
 — pregnant or lactating women. For women of child-
bearing age and for their partners, effective contra-
ception was required;
 — systemic chemotherapy received ≤ 6 months before 
PRRT.
The patients were treated at the Nuclear Medicine 
Unit of the Endocrinology Department at the University 
Hospital in Krakow from 2005–2010.
The 90Y-DOTATATE (IAE, Radioisotope Centre 
POLATOM, Poland) therapeutic activity was calculated 
per the total surface area of the patient including weight 
and height, up to the total of 7.4 GBq/m2 activity. The 
treatment schedule was three to five cycles, repeated 
every four to nine weeks. The most frequent single 
amount of activity was 3.7 GBq (100 mCi) given usu-
ally every six to seven weeks. In the event of transient 
impairment of the haematological and/or renal indices, 
the interval period was extended to a maximum of nine 
weeks. Dosimetry based calculation of the therapeutic 
doses was not possible because of the technetium labelled 
compounds used for the pre-therapeutic SRS. The first 
patients received 90Y-DOTATATE in intravenous infu-
sion lasting 30 minutes; then it was changed and bolus 
of radiolabelled somatostatin analogue was applied two 
hours after mixed amino acid administration (Vamin 18, 
Fresenius Kabi, Germany; containing among others 11.3 g 
of arginine and 9.0 of lysine/1,000 mL of solution), which 
was used for kidney protection. The Vamin 18 infusion 
was continued up to ten hours after 90Y-DOTATATE admi-
nistration. The PRRT was designed so as not to exceed the 
permissible accumulated dose for kidney (27 Gy) [10, 11].
Before and after PRRT, all patients received 
a physical examination, a quality of life assessment 
(Karnofsky’s scale), a questionnaire examination con-
cerning symptoms of disease (e.g. diarrhoea, flush, 
bronchospasm, etc.), blood testing for haematology 
(WBC with blood smear, Hb, Plt, and RBC), kidney 
function (BUN, creatinine, GFR), liver function (ALT) 
and chromogranin A (CgA). All biochemical indices 
were assessed after each cycle of the therapy, five and 
12 months post-therapy, and every month thereafter. 
The GFR value was calculated using Cockcroft-Gault’s 
formula. Estimation of GFR values for patients with 
chronic renal disease was performed in accordance with 
the recommendations of the Disease Outcome Quality 
Initiative (K/DOQI)9.
SRS and computed tomography (CT) were per-
formed in all patients before and three, six, 12, 18 and 
24 months after PRRT. [99mTc-EDDA/HYNIC]octreotate 
(740 MBq) single photon emission computed tomogra-
phy (SPECT) of abdomen and/or chest and whole body 
(WB) scans were obtained with the use of a dual-head, 
large view field E.CAM gamma camera (Siemens) 
equipped with low-energy, high resolution (LEHR) colli-
mators with e.soft operating systems. Semi-quantitative 
region of interest (ROI) analyses of the focal lesions were 
performed. Target/non target ratios, up to five focal le-
sions per scan, were compared before and after therapy.
Most CT examinations were performed with 
a 10-row helical tomograph (Siemens Sensation 10). 
Tumour response to PRRT was assessed using Response 
Criteria In Solid Tumors (RECIST).
Statistical methods
The correlation between the time to progression and the 
received activity, also the correlation between PLT levels 
after 12 months from PRRT and the received activity, 
were assessed using Spearman’s rank correlation coef-
ficient. The impact of prior chemotherapy on the time to 
progression, the bone marrow and the kidney function 
were analysed using t test. In the subgroup of patients 
with diabetes and/or hypertension, separate analyses 
of the influence of these conditions on the kidney were 
also performed using t test. The Kruskal-Wallis test was 
used to assess the relationship between the difference of 
chromogranin A values before and after the PRRT and 
the response to the treatment. The overall survival, the 
progression free survival and the event free survival were 
assessed on the basis of Kaplan-Meier survival curves. In 
analyses, a 5% (0.05) level of significance was assumed.
Statistical analysis of the data was performed using 
STATISTICA v. 9.0 (StatSoft, Inc.).
Results
Therapeutic effect
A completed schedule of 90Y-DOTATATE therapy was 
administered in 45 patients out of 46 treated, one 
having received only one cycle of PRRT. In this patient 
with uncontrollable symptomatic disease, diagnosis 
of NET was made two months prior to therapy. In 45 
patients who completed 90Y-DOTATATE therapy, after 
12 month follow-up stabilisation of disease was observed 
in 47%, partial remission in 31%, and progression in 9% 
of patients. 11% of patients died before the 12 month fol-
low up, one patient due to myocardial infarction. In one 
patient, the information after 12 months is incomplete. 
Figure 1 presents SRS results before and after the PRRT 
in the patient with partial response.
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The progression free survival was 37.4 months. The 
event free survival was 31.2 months. Overall survival 
is not culminate is not reached (the 25th percentile 
was 20.3). Progression of the disease after 12 months 
(between 13–60 months after beginning of PRRT, nine 
patients after two years) was observed in 16 patients, 
among whom seven patients died between 13 and 
40 months after beginning PRRT. Nine patients with 
progression received additional PRRT cycles between 
11 and 47 months after ending the first PRRT cycles. De-
spite repeated therapy, five of them died, at two, four, 
11, 18 and 24 months from starting repeated PRRT cy-
cles. Three patients are still repeating PRRT cycles, one 
has displayed stabilisation of the diseases after PRRT. 
A statistically significant correlation between time to 
progression and the received activity was not observed 
(p > 0.05). The overall survival, the progression free 
survival and the event free survival after the PRRT are 
shown in Figure 2.
There was no statistically significant difference in 
the survival time of patients with or without prior 
chemotherapy treatment (p = 0.13). All symptomatic 
patients in which PR or SD were achieved, were free of 
carcinoid syndrome symptoms, although in this group 
the therapy with long-acting somatostatin analogues 
was restarted after PRRT.
Side effects of PRRT
After 12 months follow-up, there were no statistically 
significant changes in the creatinine after PRRT. In this 
time, creatinine changes grade 1 were observed in 5%, 
grade 2 in 15%, and grade 4 in 5% of patients. No changes 
grade 3 in creatinine values were observed in our group 
of patients. Twelve months into therapy, an increase 
of mean creatinine values to 80 μmol/L, compared to 
a baseline of 72 μmol/L, was observed (normal range 
45–97 μmol/L). The slightly higher mean increase to 140 
μmol/L was seen in four patients 24–28 months after 
the beginning of PRRT. None of the patients from this 
group presented symptoms of renal dysfunction. In one 
patient (a 68 year-old woman) with diabetes, an increased 
value of creatinine level was observed from six months 
after PRRT. After ten months, the creatinine value was 
313 μmol/L and the patient was referred for dialysis 
therapy. The next patient, a 63 year-old woman with 
hypertension, had increases in values of creatinine level 
12 months after PRRT (350 μmol/L); 12 months later, this 
woman was referred for dialysis therapy. In both of these 
patients, regression of the disease is still observed. The 
mean creatinine levels are presented in Figure 3.
A transient decrease of blood parameters was 
observed in 62.5% of patients after PRRT. The highest 
decrease in WBC was seen after cycles III and IV of 
the therapy. At different times after PRRT, transient 
changes grade 3 (according to WHO criteria) in seven 
patients were observed; no grade 4 was observed. 
After 12 month follow-up, no grades 3 or 4 accord-
ing to WHO criteria were observed. Filgrastim was 
administered to one patient with a WBC level of 
1,360/mm3 three months into therapy. Transient de-
creases of platelets values grade 3 according to WHO 
criteria in four patients was observed at different times 
after PRRT; no grade 4 was observed. After 12 month 
follow-up, no grades 3 or 4 according to WHO criteria 
were observed. A transient decrease in platelet level 
was observed compared to baseline, but mean platelet 
values were within normal ranges.
Decreased Hb levels were observed during this 
study, with the lowest mean Hb values noted at the 
12 month follow-up following the initiation of therapy 
(11.2 g/dl) compared to baseline (13.1 g/dl). In most 
cases, mild anaemia was observed. Transient decreased 
values of Hb grade 3 according to WHO criteria in three 
patients were observed at different times after PRRT. 
Two of them after previous chemotherapy needed blood 
transfusion. One patient treated with chemotherapy 
(Gemzar) once monthly for seven years developed 
MDS. This patient died 12 months after ending PRRT. 
After 12 month follow-up, no grades 3 or 4 in Hb levels 
according to WHO criteria were observed.
The mean Hb, PLT and WBC values in patients 
before and after PRRT are given in Figure 4.
Patients treated previously with chemotherapy had 
statistically lower baseline and control leukocyte and 
platelet levels, and higher creatinine levels, than pa-
tients who were not treated with chemotherapy. There 
were no statistically significant differences in creatinine 
levels 12 months after the therapy in patients with 
arterial hypertension and diabetes in comparison with 
patients without these conditions (p > 0.05).
A decrease in chromogranin A mean marker values 
was observed in 35 out of 45 patients who completed the 
Figure 1. The SRS results with [99mTc-EDDA/HYNIC]octreotate 
before and after the PRRT in patient with partial response
Rycina 1. Wynik badania SRS z zastosowaniem [99mTc-EDTA/
/HYNIC]Octreotate przed i po terapii znakowanymi analogami 
somatostatyny u pacjenta z częściową remisją choroby
A B
396
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
90Y-DOTATATE therapy in neuroendocrine tumours Anna Sowa-Staszczak et al.
Figure 2. The Kaplan-Meier survival curves. A. The overall survival. B. The progression free survival. C. The event free survival
Rycina 2. Krzywe przeżycia Kaplana-Meiera. A. Czas całkowitego przeżycia. B. Czas wolny od progresji. C. Czas przeżycia wolny 
od jakiegokolwiek zdarzenia (progresja, śmierć)
A
B
C
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PRRT. No statistically significant relationship between 
change in chromogranin A level before and after the 
treatment and response to the treatment was found 
(p = 0.31).
No significant impairment of liver function was seen 
during or after PRRT.
Discussion
Neuroendocrine neoplasms are a relatively rare group 
of tumours and their overall incidence appears to have 
increased over the past 30 years, due in large part to 
an improvement in the diagnostic tools used for their 
detection [12]. The potential malignancy of NETs might 
be independent of their size. The clinical course is often 
unpredictable and the evidence of metastases may be 
the only indicator of malignancy [13]. When a tumour 
is disseminated or nonoperable, the possibility of radi-
cal treatment is decreased. Poor sensitivity of NETs to 
chemotherapy has led to a search for more effective 
therapies. Recent clinical studies have proven the high 
effectiveness of PRRT in NET treatment. In a multicentre 
Figure 3. Creatinine [μmol/L] levels after PRRT
Rycina 3. Stężenie kreatyniny [μmol/L] po terapii znakowanymi analogami somatostatyny
Figure 4. Hb [g/dl], PLT [103/μL], WBC [103/μL] levels after PRRT
Rycina 4. Wartości hemoglobiny [g/dl], płytek krwi [103/μl] i leukocytów [103/μl] u pacjentów po terapii znakowanymi analogami 
somatostatyny
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study by Valkema et al., 60 patients received increasing 
activities of [90YDOTA0Tyr3] octreotide to a total activity 
dose of 14.8 GBq/m2 in four cycles or 9.5 GBq/m2 in a sin-
gle cycle [14]. Partial response (PR) was seen in 8% of 
patients and a minor response in 13%, with an observed 
tumour mass reduction of 25–50%. The mean time to 
progression was 30 months in 44 patients with stable 
disease (SD), partial, or minor response to treatment. 
In the study by Waldherr et al. complete response (CR) 
was seen in 24% of patients treated with 6–7.4 GBq 
90Y-DOTATOC in four cycles [15, 16]. In another trial 
where an activity of 7.4 GBq/m2 was administered in 
two greater intervals between cycles, CR or PR were 
achieved in 33% of 36 patients, without an increase in 
side effects [17]. When using a 7.4 GBq activity in four 
cycles each given six weeks apart, a CR was observed 
in two of 39 patients, PR in 18%, SD in 69%, and disease 
progression in 8%. Two patients died three months after 
treatment due to progression of disease and liver dys-
function. In one of these cases, there was liver damage 
resulting from bacterial cholangitis following the third 
cycle of therapy [16].
In our study, the treatment response was evaluated 
at 12 months following the onset of therapy. After exclu-
ding the patient who died before completing the PRRT, 
the progression free survival was 37.4 months. Varying 
time periods of response to treatment from 9-30 months 
have been reported in the literature [15, 18–19]. In the 
study by Valkema et al., there were increasing activities 
of 90Y-DOTATOC to a total activity of 14.8 GBq in four 
cycles or 9.5 GBq in a single cycle. Despite the protracted 
time of response to treatment, merely 8% of patients had 
PR after maximal activity was used [14].
However, when different protocols of 90Y-DOTA-
TOC treatment are used, the response to treatment 
(CR, PR) increases to 10–30%. This is a better result in 
comparison with other therapies, including therapy 
with 111In-DTPA-octreotide. Upon comparing our 
results with those of Waldherr et al. which used the 
same intravenous cumulative activity, we observed 
a higher percentage of disease remission, but a lower 
percentage of disease stabilisation [16]. There was 
a similar percentage of patients with progression of 
disease in our study, but a higher number of partici-
pants who died before the end of therapy (12 month 
follow-up). This could be related to delayed diagnosis, 
with patients admitted to the trials who were in more 
advanced stages of disseminated disease. Among pa-
tients who received the whole planned therapy regi-
men, the response to treatment was 78% (remission 
and stabilisation).
In a case of advanced neoplastic disease, this is a very 
good response in comparison with the methods used 
thus far in the treatment of NETs [16]. When analysing 
the group of patients with disease progression, where 
most progression was between 12 and 24 months (nine 
patients) after PRRT, it appears that our treatment regi-
men can prolong life.
Recent reports have shown the effectiveness of 
octreotide LAR in reducing the risk of neuroendocrine 
tumour progression (the PROMID study) [20].
In our study, in ten patients receiving a long-acting 
somatostatin analogue, we were not able to assess the 
impact of the treatment as the therapy was no longer 
then three months.
Renal injury is the most serious side effect of PRRT. 
The renal radiation dose clearly limits the level of iso-
tope activity which can be used safely. The long-term 
monitoring of renal function post-therapy is very 
important to evaluate the risk of clinically significant 
renal failure [9]. Renal injury following PRRT was ob-
served during early studies with somatostatin analogue 
therapy where issues of kidney protection were not 
addressed. In 1997, Otte et al. used increasing doses 
to a cumulative activity of 6 ± 1.34 GBq/m2 in patients 
with GEP-NET.
In 83% of patients, no significant renal dysfunction oc-
curred at cumulative activities ≤ 7.4 GBq. In five patients, 
there was toxic renal injury observed at cumulative activi-
ties ≥ 7.4 GBq. Increased creatinine levels were observed 
two to four months following the final treatment cycle 
[17,18]. Sporadic cases of delayed renal failure or terminal 
renal failure were observed by Brans et al. in patients who 
received activities > 7.4 GBq/m2 [19].
Bodei et al. monitored patients treated with 
90 Y- DOTATOC for up to eight years and reported cre-
atinine toxicity in nine out of 23 patients’ cases within 
one to five years following radionuclide therapy. Eight 
of the nine patients demonstrating toxicity had pre-ex-
istent risk factors. Higher (> 30%) losses of creatinine 
clearance occurred in patients showing toxicity [21].
The infusion of arginine and lysine reduces the dose 
absorbed by kidneys by 9–53% [22, 23]. The protective 
effect of arginine and lysine administered both before 
and after therapy with different 90Y-DOTATOC activi-
ties of up to 5.55 GBq activity per cycle was observed 
by Bodei et al. [22].
In our study, lysine and arginine infusion was be-
gun two to three hours before radioisotope therapy, 
and continued for ten hours. No noticeable acute 
renal failure was observed after therapy, which we 
believe was due to the protective effect of amino acids 
in addition to the fact that the maximum activity did 
not exceed 7.4 GBq during the entirety of the treat-
ment regimen, with a cumulative dose for kidneys of 
under 27 Gy [17–19, 22]. We also observed increased 
creatinine levels and decreased GFR during prolonged 
observation following treatment. According to the 
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literature, toxic renal failure can occur from two to five 
months or up to several years after therapy [16, 17, 22, 
23]. Prolonged observation was performed in all of the 
living patients in our study and all of these patients 
are still in the observational group.
For patients treated with 90Y-DOTATOC, hyperten-
sion, age, diabetes and renal radiation dose > 14 Gy 
per cycle are considered risk factors for a decline in 
creatinine clearance (CLR) of > 20% and an associated 
high risk of ESRD (defined as CLR < 15 mL/min/1.73 m2) 
within five years of therapy [24]. In our study, there 
was no observed influence of coexisting diabetes and 
hypertension on renal parameters.
The haematological toxicity of grades 3 or 4 (WHO 
criteria) of leucocytes, granulocytes, or platelets occurs 
relatively rarely and is usually transient. Myelotoxicity 
due to bone marrow suppression is observed follow-
ing high doses of PRRT where the estimated radiation 
dose for bone marrow is 3 Gy. However, even with 
an absorbed dose lower than the anticipated limit dose 
for toxicity (particularly in bone marrow), repeated 
doses may produce haematological toxicity. Acute 
haematological toxicity of grades 3 and 4 might occur 
after [90Y-DOTA0,Tyr3] octreotide therapy, and sporadic 
cases of myelodysplastic syndrome may occur follow-
ing administration of any of these radionuclides [19].
Paganelli et al. described transient lymphocyto-
penia after 90Y-DOTATOC treatment in nearly all pa-
tients. There was no correlation between the dose and 
the degree of lymphocytopenia, and eventual return 
to normal levels was observed in all patients. Toxicities 
at grades 0 to 1 occurred at activities greater than 5.55 
GBq. Among patients who received activities within 
the range of 6.66–7.77 GBq, 41.7% demonstrated hae-
matological toxicity at grade 2 but, in all cases, values 
returned to normal within four to six weeks. This ob-
servation was probably due to the low dose delivered 
to the bone marrow which was estimated by dosimetric 
examination [25].
Chinol et al. used increasing activities of 90Y-DOTA-
TOC, with a cumulative activity of 7.4–21.3 GBq. Revers-
ible haematological toxicity at grade 3 was observed in 
43% of patients who received 5.2 GBq, and was defined 
as the maximum tolerated activity per cycle [26]. In the 
Valkema et al. study, myelodysplastic syndrome was 
seen in three of six patients after a whole cumulative 
activity of 100 GBq (2.7 Ci). In one case, chemotherapy 
was introduced before the radioisotope therapy and 
this may explain the severe side effect [27].
In our study, 62.5% of patients had a transient 
decrease in blood parameters, particularly leuco-
cytes. Toxicities of grades 1 and 2, usually of transient 
nature, were dominant, as reported elsewhere [1, 
16, 25]. One patient in the present study experien-
ced a decrease in leukocyte levels lasting five to six 
months, but there were no symptoms of severe my-
elotoxity, including infections, observed in any of the 
patients. Similarly to the Waldherr et al. study, we 
observed decreased leukocyte values for several days 
post-therapy, but values normalised between treat-
ment cycles and all patients were able to continue 
therapy [16]. Lower primary levels of leucocytes and 
platelets were seen among patients who had received 
chemotherapy prior to this study. As in the Paganelli 
et al. study, there was no correlation between the 
received activity and the degree of leucopenia after 
12 months after the therapy [25].
Platelet numbers decreased following each cycle of 
therapy, but the effect was transient for leukocytes. In 
the majority of patients, decreases in platelet levels 
were present only compared to baseline values, with 
levels remaining within normal ranges. The same ef-
fect was seen for haemoglobin values and there was no 
need to suspend radiotherapy [16]. One of our patients 
developed MDS, perhaps as a consequence both of the 
chemotherapy (used for a long time i.e. repeated every 
month for seven years) and of the PRRT. 
As in other published studies, in our study, liver 
toxicity was transient and occurred particularly when 
liver metastases were present [1].
Conclusions
Our study suggests that therapy of neuroendocrine 
tumours with 90Y-DOTATATE can result in symptomatic 
relief and tumour mass reduction. Further studies on 
the influence of PRRT on patient survival are needed. 
The mild critical organ toxicity observed does not limit 
the PRRT of NETs.
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